PL3402802T3 - Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym - Google Patents
Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowymInfo
- Publication number
- PL3402802T3 PL3402802T3 PL17736506.1T PL17736506T PL3402802T3 PL 3402802 T3 PL3402802 T3 PL 3402802T3 PL 17736506 T PL17736506 T PL 17736506T PL 3402802 T3 PL3402802 T3 PL 3402802T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- generating
- methods
- immune response
- associated antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001181—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276479P | 2016-01-08 | 2016-01-08 | |
US201662301885P | 2016-03-01 | 2016-03-01 | |
PCT/US2017/012704 WO2017120577A1 (en) | 2016-01-08 | 2017-01-09 | Compositions and methods for generating an immune response to a tumor associated antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3402802T3 true PL3402802T3 (pl) | 2023-06-05 |
Family
ID=59274065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17736506.1T PL3402802T3 (pl) | 2016-01-08 | 2017-01-09 | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
Country Status (9)
Country | Link |
---|---|
US (3) | US11278607B2 (pl) |
EP (1) | EP3402802B1 (pl) |
JP (3) | JP7150611B2 (pl) |
CN (2) | CN116064669A (pl) |
AU (2) | AU2017206102C1 (pl) |
CA (1) | CA3011014A1 (pl) |
ES (1) | ES2944314T3 (pl) |
PL (1) | PL3402802T3 (pl) |
WO (1) | WO2017120577A1 (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017206102C1 (en) | 2016-01-08 | 2022-02-10 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
US20210220469A1 (en) * | 2017-08-25 | 2021-07-22 | Geovax, Inc. | Immuno-Oncology Compositions and Methods for Use Thereof |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
WO2020073045A1 (en) * | 2018-10-05 | 2020-04-09 | Nantcell, Inc. | Cd40 and cd40l combo in an adenovirus vaccine vehicle |
MX2022005601A (es) * | 2019-11-20 | 2022-08-15 | Bavarian Nordic As | Usos médicos de virus vaccinia ankara modificado (mva) recombinante con adyuvante de ligando de 4-1bb (4-1bbl). |
MX2022009962A (es) * | 2020-02-14 | 2022-11-09 | Geovax Inc | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. |
JP2021187810A (ja) * | 2020-06-04 | 2021-12-13 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよびその利用 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
WO1984002077A1 (en) | 1982-11-30 | 1984-06-07 | Us Health | Process for producing poxvirus recombinants for expression of foreign genes |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
EP0538496B1 (en) | 1991-08-26 | 2003-10-29 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
US5445953A (en) | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
DE69229390T2 (de) | 1991-08-26 | 1999-11-11 | Immuno Ag, Wien | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
WO1994012617A1 (en) | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
AU4088697A (en) | 1996-08-26 | 1998-03-19 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
AUPP380598A0 (en) | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
EP2388015A1 (en) | 2000-03-02 | 2011-11-23 | Emory University | DNA expression vectors and methods of use |
US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
DK1372710T3 (da) | 2001-03-08 | 2010-01-18 | Us Gov Health & Human Serv | MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener |
EP1279404A1 (en) | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US7211378B2 (en) * | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
WO2003078640A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Recombinant drug-sensitive vaccinia virus as smallpox vaccine |
SI1407033T1 (sl) | 2002-05-16 | 2006-06-30 | Bavarian Nordic As | Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA) |
US20060088909A1 (en) | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
WO2003106648A2 (en) * | 2002-06-14 | 2003-12-24 | Diadexus, Inc. | Compositions and methods relating to breast specific genes and proteins |
DE10249390A1 (de) | 2002-10-23 | 2004-05-13 | Ruprecht-Karls-Universität Heidelberg | Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria |
US20040109876A1 (en) | 2002-11-25 | 2004-06-10 | Kureha Chemical Industry Co., Ltd. | Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV |
AU2003293675B2 (en) | 2002-11-25 | 2009-04-23 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ATI promoters |
EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
US20060099225A1 (en) | 2004-04-13 | 2006-05-11 | Sina Bavari | Generation of virus-like particles and use as panfilovirus vaccine |
WO2006031264A2 (en) | 2004-05-25 | 2006-03-23 | Oregon Health And Science University | Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors |
WO2006026667A2 (en) | 2004-08-27 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
EP1683870A1 (en) | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
EP2526957A3 (en) * | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
WO2006130525A2 (en) | 2005-05-31 | 2006-12-07 | Sidney Kimmel Cancer Center | Methods for immunotherapy of cancer |
ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
NZ573437A (en) | 2006-06-20 | 2012-02-24 | Transgene Sa | Process for producing poxviruses and poxvirus compositions |
WO2008008881A1 (en) | 2006-07-13 | 2008-01-17 | Emory University | Virosomes, methods of preparation, and immunogenic compositions |
CN101563463B (zh) | 2006-08-25 | 2013-03-27 | 美国国有健康与人类服务部(马里兰州) | 修饰的安卡拉(mva)痘苗病毒基因的基因组中保守基因之间的基因间位点 |
US20090092628A1 (en) | 2007-03-02 | 2009-04-09 | James Mullins | Conserved-element vaccines and methods for designing conserved-element vaccines |
WO2009009215A2 (en) | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
ES2496916T3 (es) | 2007-05-31 | 2014-09-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas |
US11202775B2 (en) * | 2007-09-25 | 2021-12-21 | Minerva Biotechnologies Corporation | Methods for treatment of cancer |
US20100330190A1 (en) | 2007-12-17 | 2010-12-30 | Compans Richard W | Immunogenic compositions and methods of use thereof |
JP5683476B2 (ja) | 2008-11-03 | 2015-03-11 | タケダ ヴァクシーンズ, インコーポレイテッド | 感染因子を含まないエンベロープウイルスベースvlpを単離するための改良法 |
US20120219576A1 (en) | 2009-09-16 | 2012-08-30 | The Administrators Of The Tulane Educational Fund | Lassa virus-like particles and methods of production thereof |
AP2012006258A0 (en) | 2009-10-13 | 2012-06-30 | Geovax Inc | Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. |
WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
WO2011093858A1 (en) * | 2010-01-27 | 2011-08-04 | Oregon Health & Science University | Cytomegalovirus-based immunogenic preparations |
CA2790426A1 (en) | 2010-02-18 | 2011-08-25 | Emory University | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response |
US20120052082A1 (en) | 2010-04-09 | 2012-03-01 | Zetra Biologicals, LLC | Cross-protective influenza vaccine |
EP3466440A1 (en) | 2010-04-16 | 2019-04-10 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
CN103209701B (zh) | 2010-06-11 | 2016-08-03 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
CN103458922B (zh) * | 2011-01-31 | 2017-10-03 | 纳米医疗公司 | 诱导对甲型流感病毒的异源亚型免疫反应的重组病毒载体和方法 |
CN103945863A (zh) | 2011-08-01 | 2014-07-23 | 爱默蕾大学 | 包含配体的vlp及其相关方法 |
WO2013059498A1 (en) | 2011-10-18 | 2013-04-25 | Geovax, Inc. | Mva vectors expressing polypeptides and having high level production in certain cell lines |
US9463238B2 (en) | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
JP2015522580A (ja) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | 免疫学的組成物およびその使用 |
US9821046B2 (en) | 2013-01-21 | 2017-11-21 | Oxford University Innovation Limited | Composition and uses thereof |
WO2015009946A1 (en) | 2013-07-17 | 2015-01-22 | Emory University | Method of increasing immune response to hiv antigens |
AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
WO2015066715A1 (en) * | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
JP2017515841A (ja) * | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びtim−3に対するモノクローナル抗体を用いた癌治療のための併用療法 |
CN106999565B (zh) * | 2014-09-03 | 2021-03-05 | 巴法里安诺迪克有限公司 | 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗 |
WO2016068919A1 (en) | 2014-10-29 | 2016-05-06 | Geovax, Inc. | Combination therapy for treating viral reservoirs |
EP3244919A4 (en) | 2015-01-12 | 2018-06-27 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
US10072058B2 (en) | 2015-04-29 | 2018-09-11 | Emory University | Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates |
AU2017206102C1 (en) | 2016-01-08 | 2022-02-10 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
US11098086B2 (en) | 2016-02-16 | 2021-08-24 | Geovax Inc. | Multivalent HIV vaccine boost compositions and methods of use |
CN109641044A (zh) | 2016-05-30 | 2019-04-16 | 吉奥瓦科斯公司 | 用于产生对乙型肝炎病毒的免疫应答的组合物和方法 |
WO2018195447A1 (en) | 2017-04-20 | 2018-10-25 | Geovax Labs, Inc. | Recombinant mva-based hiv immunogens and uses thereof |
WO2019018501A1 (en) | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
US20210220469A1 (en) | 2017-08-25 | 2021-07-22 | Geovax, Inc. | Immuno-Oncology Compositions and Methods for Use Thereof |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
WO2020247547A1 (en) | 2019-06-03 | 2020-12-10 | Geovax, Inc. | Cancer vaccine compositions and methods for use thereof |
-
2017
- 2017-01-09 AU AU2017206102A patent/AU2017206102C1/en active Active
- 2017-01-09 PL PL17736506.1T patent/PL3402802T3/pl unknown
- 2017-01-09 CN CN202210789628.9A patent/CN116064669A/zh active Pending
- 2017-01-09 CN CN201780016086.9A patent/CN109071592B/zh active Active
- 2017-01-09 CA CA3011014A patent/CA3011014A1/en active Pending
- 2017-01-09 EP EP17736506.1A patent/EP3402802B1/en active Active
- 2017-01-09 ES ES17736506T patent/ES2944314T3/es active Active
- 2017-01-09 WO PCT/US2017/012704 patent/WO2017120577A1/en active Application Filing
- 2017-01-09 US US16/068,527 patent/US11278607B2/en active Active
- 2017-01-09 JP JP2018554648A patent/JP7150611B2/ja active Active
-
2020
- 2020-02-20 US US16/796,350 patent/US11413341B2/en active Active
-
2021
- 2021-11-05 AU AU2021261945A patent/AU2021261945A1/en active Pending
-
2022
- 2022-07-29 US US17/876,682 patent/US20230040403A1/en active Pending
- 2022-09-27 JP JP2022153352A patent/JP2022185011A/ja not_active Ceased
-
2024
- 2024-02-13 JP JP2024019248A patent/JP2024056839A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017206102A1 (en) | 2018-07-19 |
AU2017206102C1 (en) | 2022-02-10 |
US20190290745A1 (en) | 2019-09-26 |
CN109071592A (zh) | 2018-12-21 |
JP2019500907A (ja) | 2019-01-17 |
ES2944314T3 (es) | 2023-06-20 |
US11413341B2 (en) | 2022-08-16 |
JP7150611B2 (ja) | 2022-10-11 |
US11278607B2 (en) | 2022-03-22 |
AU2021261945A1 (en) | 2021-12-02 |
US20230040403A1 (en) | 2023-02-09 |
EP3402802A1 (en) | 2018-11-21 |
CN116064669A (zh) | 2023-05-05 |
JP2022185011A (ja) | 2022-12-13 |
JP2024056839A (ja) | 2024-04-23 |
CA3011014A1 (en) | 2017-07-13 |
AU2017206102B2 (en) | 2021-08-26 |
WO2017120577A1 (en) | 2017-07-13 |
US20200289633A1 (en) | 2020-09-17 |
CN109071592B (zh) | 2022-07-19 |
EP3402802A4 (en) | 2019-08-21 |
EP3402802B1 (en) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3402802T3 (pl) | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym | |
HK1255637A1 (zh) | 免疫檢查點嵌合受體療法 | |
GB201708444D0 (en) | Compositions and methods for inducing an immune response | |
IL251435A0 (en) | Preparations and methods of use for increased immune response and cancer treatment | |
IL265434A (en) | Anti-cd27 antibodies | |
GB2538410B (en) | Generating three-dimensional objects | |
GB2538419B (en) | Generating three-dimensional objects | |
GB2538409B (en) | Generating three-dimensional objects | |
IL247614A0 (en) | Methods and preparations for changing the immune response | |
IL250818A0 (en) | Methods and preparations for increasing immune responses | |
IL248079A0 (en) | Methods for increasing the efficiency of a tumor-directed immune response | |
GB2538411B (en) | Generating three-dimensional objects | |
EP3288538A4 (en) | Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines | |
HK1250637A1 (zh) | 用於引發免疫應答的劑和組合物 | |
GB201621686D0 (en) | Novel methods for inducing an immune response | |
HK1254514A1 (zh) | 用於增强疫苗接種免疫反應的方法及組合物 | |
IL245509B (en) | Compositions and methods for inducing an enhanced immune response using pox virus vectors | |
ZA201605955B (en) | Novel methods for inducing an immune response | |
IL252644A0 (en) | Vaccines based on jaundice core antigens b | |
EP3097420A4 (en) | Methods and compositions for immune dis-inhibition | |
IL247295A0 (en) | Components based on antigens with a yellow core b | |
EP3488994C0 (en) | GENERATION OF THREE-DIMENSIONAL OBJECTS |